Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing ...
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...
The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...
6d
News Medical on MSNExploring ketamine's potential in the fight against treatment-resistant depressionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
6d
Pharmaceutical Technology on MSNSupernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
In reality, most people living on the street are not uniquely immune to mental health interventions — they are uniquely ...
It is now approved for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster ...
Bryan Johnson injected himself with ketamine, a hallucinogen favored by Elon Musk, for 15 days. He used a helmet from his ...
Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results